---
title: Biomay AG vs eXmoor Pharma
slug_a: biomay
slug_b: exmoorpharma
site: cdmo
review_signal_gate: closed
canonical_path: /compare/biomay/exmoorpharma
---

# Biomay AG vs eXmoor Pharma

Side-by-side profile data from each company listing on this directory.

## Biomay AG

- Profile: [/companies/biomay](/companies/biomay)

Biomay AG — GMP CDMO specializing in plasmid DNA, mRNA, and recombinant protein manufacturing from gene construction to market supply, with in-house mRNA lipid-nanoparticle formulation and aseptic fill-finish capabilities.

Services: 8. Modalities: 2. Indications: 0. Locations: 1. Certifications: 1. The strongest documented coverage currently appears in services (8).

### Services

- Recombinant Protein Manufacturing
- Cell-Line Development
- mRNA Manufacturing
- Lipid Nanoparticle (LNP) Formulation
- Sterile Fill-Finish & Aseptic Manufacturing
- Process Development
- CMC Analytical Development
- CMC Regulatory Submission Support

### Modalities

- mRNA
- Gene Therapy

### Development capabilities

- Formulation development

### Manufacturing capabilities

- Drug Substance (DS)
- Drug Product (DP)
- Liquid Vials
- Expression: Mammalian
- Expression: Microbial

## eXmoor Pharma

- Profile: [/companies/exmoorpharma](/companies/exmoorpharma)

eXmoor Pharma — Integrated cell and gene therapy CDMO with 20+ years of consultancy expertise, offering end-to-end CMC support from early-phase strategy through GMP manufacturing across viral vectors, autologous/allogeneic cell therapies, and RNA technologies.

Services: 9. Modalities: 3. Indications: 0. Locations: 1. Certifications: 0. The strongest documented coverage currently appears in services (9).

### Services

- Viral Vector Manufacturing
- Cell Therapy Manufacturing
- Autologous Cell Therapy Manufacturing
- Allogeneic Cell Therapy Manufacturing
- mRNA Manufacturing
- Sterile Fill-Finish & Aseptic Manufacturing
- Process Development
- CMC Analytical Development
- CMC Regulatory Submission Support

### Modalities

- mRNA
- Cell Therapy
- Gene Therapy

### Development capabilities

- Analytical method development
- Formulation development
- Cell line development

### Manufacturing capabilities

- Drug Substance (DS)
- Drug Product (DP)
- Liquid Vials
- Max bioreactor: Mid-scale clinical (≤2,000 L)
- Single-Use / Disposable